Novo Nordisk A/S (NVO) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Q1 2025 Novo Nordisk AS Earnings Conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you will need to press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 and 1 again. Please be advised that today's conference is being recorded. I would now like to have the comments of your first speaker today, Jakob Rode, Head of Investor Relations. Please go ahead, sir. Thank you. And welcome to this Novo Nordisk earnings call for the first three months of 2025. My name is Jakob Rode, and I'm the Head of Investor Relations at Novo Nordisk. And with me today I have CEO of Novo Nordisk, Lars Brugger Jørgensen, Executive Vice President, U.S. Operations, Dave Moore, Executive Vice President, International Operations, Mike Duster, Executive Vice President and Head of Development, Martin Holtz-Lange, and finally, Chief Financial Officer, Carsten von Klosen. All speakers will be available for the Q&A session. Today's announcement and the slides for this call are available on our website, nominoids.com. Please note that the call is being webcasted live, and a recording will be made available on our website as well. The call is scheduled to last one hour. Next slide, please. The presentation is structured as outlined on slide two. Please note that all sales and operating profit growth statements will be at constant exchange rates unless otherwise specified. Please turn to the next slide. We need to advise you that this call will contain forward-looking statements. These are subject to risk and uncerta...